Breast cancer is a common cancer with a leading cause of cancer mortality in women. Currently, the chemotherapy for breast cancer is underdeveloped. Here, we report a novel taspine derivative, HMQ1611, which has anticancer effects using in vitro and in vivo breast cancer models. HMQ1611 reduced cancer cell proliferation in four human breast cancer cell lines including MDA-MB-231, SK-BR-3, ZR-75-30, and MCF-7. HMQ1611 more potently reduced growth of estrogen receptor a (ERa)-positive breast cancer cells (ZR-75-30 and MCF-7) than ERa-negative cells (MDA-MB-231 and SK-BR-3). Moreover, HMQ1611 arrested breast cancer cell cycle at S-phase. In vivo tumor xenograft model, treatment of HMQ1611 significantly reduced tumor size and weight compared with vehicles. We also found that HMQ1611 reduced ERa expression and inhibited membrane ERa-mediated mitogenactivated protein kinase (MAPK) signaling following the stimulation of cells with estrogen. Knockdown of ERa by siRNA transfection in ZR-75-30 cells attenuated HMQ1611 effects. In contrast, overexpression of ERa in MDA-MB-231 cells enhanced HMQ1611 effects, suggesting that ERa pathway mediated HMQ1611 0 s inhibition of breast cancer cell growth in ERa-positive breast cancer. HMQ1611 also reduced phosphorylation of EGF receptor (EGFR) and its downstream signaling players extracellular signal-regulated kinase (ERK)1/2 and AKT activation both in ZR-75-30 and MDA-MB-231 cells. These results showed that the novel compound HMQ1611 had anticancer effects, and partially via ERa and/or EGFR signaling pathways, suggesting that HMQ1611 may be a potential novel candidate for human breast cancer intervention. Cancer Prev Res; 1-10. Ó2012 AACR.
Introduction
Breast cancer is a common cancer with high mortality among women. Currently the chemotherapy of breast cancer is underdeveloped although there are some molecules that have been identified as drug targets including estrogen receptor a (ERa). ERa plays an important role in tumor formation and progression. More than 70% of breast tumors have been diagnosed as ERa-positive expression (1) (2) (3) . ERa is a member of the large superfamily of nuclear receptors acting as a ligand-activated transcription factor (4-7), which binds to 17b-estradiol (E2) and combines with specific estrogen response elements (ERE) in the promoters of target genes in the nucleus. In addition to this genomic mechanism of ERa, increasing experimental evidence has showed its nongenomic effect, which can be rapidly activated by estrogen (8) (9) (10) (11) (12) . The membrane ERa can also transactivate insulin-like growth factor 1 receptor (IGF-1R) and EGF receptor (EGFR)/HER2, which leads to the activation of the downstream extracellular signal-regulated kinases (ERK) signaling cascade (13) (14) (15) . For ERapositive breast cancer, anti-ER treatment strategies involve selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators, and disruption of estrogen synthesis (16) (17) (18) . However, the long-term anti-ER treatment results in drug resistance due to activation of HER2/EGFR growth factor receptor pathway (19) (20) (21) .
Evidence suggests that EGFR overactivation is frequently related to the development of cancer and increase of tumor cell proliferation (22) . There are at least 30% of breast cancers expressing EGFR (23, 24) . The EGFR is a transmembrane tyrosine kinase that belongs to the HER/ErbB protein family (25) . Ligands such as EGF and TGFa binding to EGFR result in receptor homo-or heterodimerization with another member of the HER/ErbB family, followed by autophosphorylation of the tyrosine residues of the intracellular domain of EGFR/HER1 (26) . These tyrosine phosphorylated sites allow proteins to bind through their Src homology 2 (SH2) domains leading to the activation of the downstream signaling cascades such as the Ras/mitogen-activated protein kinase (MAPK) pathway, the phosphoinositide-3 kinase (PI3K)/Akt pathway and the phospholipase-Cg/protein kinase C (PLCg/PKC) pathway (27) (28) (29) . These signal pathways regulate cellular proliferation, angiogenesis, and inhibition of apoptosis, which play critical roles in breast cancer pathogenesis. Drugs blocking both the ERa and the EGFR pathways have been reported to enhance antitumor effects compared with those agents that only affect one pathway (30, 31) . Thus, development of the novel drugs targeting both ERa and EGFR signaling becomes a promising cancer treatment strategy.
Taspine was initially identified by screens of Radix et Rhizoma leonticis (Hong Mao Qi in Chinese) using cell membrane chromatography by Li and He (32) . Taspine has many pharmacologic actions such as bacteriostasis, antibiosis, antivirus, anti-inflammatory, antiulcer, and anticancer effects (33) . Previously, we found that taspine displayed good affinity characteristics in a cell membrane chromatography model stably overexpressing EGFR (34) and could be used as a lead compound for searching novel anticancer agents. We have designed and synthesized a series of ring-opened and biphenyl taspine derivatives with increasing activity and solubility (35) (36) (37) . With the biologic assay screens of taspine derivatives, we found that compound HMQ1611 (Fig. 1A) exhibits the most potent pharmacologic effects (37) . In this study, we further characterized the anticancer effects of HMQ1611 in 4 breast cancer cell lines and an in vivo mouse model. We further investigated the signaling mechanisms underlying HMQ1611 inhibition of breast cancer growth. We found that HMQ1611 inhibited breast cancer growth by blocking both the ERa and the EGFR pathways. These finding suggest that HMQ1611 can be a very promising candidate for breast cancer intervention.
Materials and Methods

Drugs
Taspine derivate HMQ1611 was synthesized at our laboratory in the Natural Drug Research and Engineering Center of Xi'an Jiaotong University (Shaanxi Province, PR China) as described (ref. 37 ; Fig. 1A ).
Cell lines
ZR-75-30, MCF-7, SK-BR-3, and MDA-MB-231 breast cancer cell lines were obtained from Shanghai Institute of Cell Biology (Shanghai, PR China) in the Chinese Academy of Sciences in 2010. The cumulative culture length of these cells was fewer than 6 months after resuscitation. Cell line authentication was conducted by the provider via DNA fingerprinting, mycoplasma tests, and isozyme detection. In our laboratory, cell morphology, growth curve, and mycoplasma contamination were regularly checked to ensure the absence of contamination during the culture. MCF-7 and ZR-75-30 are ERa-positive expression cell lines (38) (39) (40) (41) . SK-BR-3 and MDA-MB-231 are ERa-negative cell lines (42, 43 
Immunoblotting analysis
Cells were harvested and lysed in RIPA Lysis Buffer (Applygen Technologies) supplemented with protease inhibitor cocktail tablets and phosphatase inhibitor cocktail tablets (Roche). The cell lysates were centrifuged at 12,000 Â g at 4 C for 10 minutes. Protein concentration of the supernatants was determined by a protein assay kit (Bio-Rad Laboratories). Equivalent amount of protein was resolved by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked in TBS containing 0.05% Tween-20 (TBST) and 5% nonfat powdered milk and then probed with different primary and secondary antibodies. Proteins were detected by using enhanced chemiluminescence reagents (Thermo). The primary antibodies include anti-ERa (1:500 dilution; Epitomics, Inc.), anti-EGFR, anti-p-EGFR (1:500 dilution; Cell Signaling Technology), anti-MEK1/2, anti-p-MEK1/2, anti-ERK1/2, anti-p-ERK1/2, anti-AKT, anti-p-AKT (1:1,000 dilution; Cell Signaling Technology), anti-PLCg, anti-p-PLCg (1:1,000 dilution; Upstate), and anti-GAPDH (1:1,000 dilution; Proteintech) antibodies.
Reverse transcriptase PCR and quantitative real-time PCR Total RNA was extracted by the RNAfast2000 kit (Fastagen) according to the manufacturer's protocol. The reverse transcriptase PCR (RT-PCR) was carried out by PrimeScript RT Master Mix Perfect Real Time Kit (TaKaRa DRR036A). Real-time PCR was carried out using SYBR Premix Ex Taq II and a Thermal Cycle Dice Real Time System (TaKaRa). The result was analyzed with the manufacturer's program (Thermal Cycler Dice Real Time System). The primer sequences were as follows:
Melt curve analysis was conducted at the end of each PCR to confirm the specificity of the PCR product. Threshold cycle (C t ) values of ERa in each sample were normalized with the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.
In vivo tumor model and immunohistochemistry
All animal experiments were carried out according to the guidelines and approval of the Institutional Animal Care and Use Committee of Xi'an Jiaotong University. Six-weekold immunodeficient female BALB/c mice were purchased from Shanghai Laboratory Animal center of the Chinese Academy of Sciences and housed under aseptic and ventilated condition. The mice were inoculated by subcutaneous injection into the mammary fat pad with ZR-75-30 cells resuspended in 5% saline. Tumor size was measured on alternate days by using a vernier caliper and calculated by length Â width 2 Â 0.5 (in cm   3 ). Body weights were monitored weekly as an indicator of overall health. Treatment began when tumors were palpable and no less than 0.1 cm 3 in volume. The mice were randomly assigned to control and treatment groups (n ¼ 8 per group). Animals were administrated orally with HMQ1611 daily at doses of 50, 100 and 200 mg/kg, respectively, whereas control animals received equivalent volumes of dissolvent. After a total of 21 days of treatment, mice were sacrificed and tumor tissue was removed, weighed, and fixed in 4% paraformaldehyde for immunohistochemical analysis. Tumor specimens were embedded into paraffin and the paraffin sections (4-mm thick) were used for immunostaining with anti-ERa (1:200 dilution, Epitomics, Inc.). For quantitative analysis, images from 6 random fields of each section were analyzed using an image quantitative analysis system (Image-Pro Plus).
Statistical analysis
All values are expressed as means AE SEM. Statistics was determined with ANOVA. Results were considered statistically significant if the P value was less than 0.05.
Results
HMQ1611 suppresses breast cancer cell growth HMQ1611 was synthesized as described previously (37) . To assess the effects of HMQ1611 on breast cancer cell growth, breast cancer cells (MDA-MB-231, SK-BR-3, MCF-7, and ZR-75-30) were treated with HMQ1611 at 0, 2, 10, 50 mmol/L concentrations. Cell viability was measured using WST-1, an antiproliferative assay. MCF-7 and ZR-75-30 cells are positively expressed ERa whereas MDA-MB-231 and SK-BR-3 cell are not (38) (39) (40) (41) (42) (43) . HMQ1611 decreased the cell viabilities of the 4 types of cancer cells (Fig. 1B) . HMQ1611 showed more suppressive effect in MCF-7 and ZR-75-30 cell growth than in MDA-MB-231 and SK-BR-3 cells. Furthermore, HMQ1611 inhibited ERa-positive cells, ZR-75-30 in a dose-and time-dependent manner (Fig. 1C) . The 50% growth inhibitory concentrations (IC 50 ) of HMQ1611 at 24, 48, and 72 hours were 29.31, 15.75, and 6.13 mmol/L, respectively.
To further explore the effects of HMQ1611 on the cell cycle, the cell-cycle profiles of ZR-75-30 were assessed with flow cytometric analysis. Cells were treated with HMQ1611 at 2.5, 5, 10 mmol/L concentrations for 48 hours and stained with propidium iodide. The cells were subjected to flow cytometric analysis to detect the DNA content. HMQ1611 treatment caused a significant increase of cells in the S-phase and a corresponding decreased proportion of cells in the G 0 -G 1 and G 2 -M phases (Fig. 1D) . We suggest that S-phase arrest may be due to the G 1 -S transition increasing in the stage of HMQ1611 treatment.
ERa signaling pathway partially mediates HMQ1611-suppressing breast cancer cell growth
To further investigate the effect of HMQ1611 on ERa expression, real-time PCR and immunoblotting assay were used to examine mRNA and protein expression after the cells were treated with HMQ1611 for 48 hours. HMQ1611 decreased ERa expression at both the mRNA and the protein levels in a dose-dependent manner in ZR-75-30 cells ( Fig.  2A-C) . Knockdown of ERa by siRNA in ZR-75-30 significantly attenuated the inhibitory effects of HMQ1611 on proliferation (Fig. 2D-F 
EGFR signaling pathway is involved in HMQ1611-suppressing breast cancer cell growth
We also determined the effect of HMQ1611 on EGFR signaling pathway. ZR-75-30 cells were treated with HMQ1611 for 48 hours followed by 100 nmol/L EGF stimulation for 10 minutes. The cell lysates were subjected to Western blot analysis with various antibodies including anti-EGFR, anti-p-EGFR, anti-MEK1/2, anti-p-MEK1/2, anti-ERK1/2, anti-p-ERK1/2 anti-AKT, anti-p-AKT, antiPLCg, anti-p-PLCg, and anti-GAPDH antibodies. As shown in Fig. 3A , treatment of HMQ1611 significantly decreased EGF-induced EGFR phosphorylation, ERK1/2 phosphorylation, and AKT phosphorylation. There was no change in PLCg phosphorylation. Moreover, we also found that HMQ1611 reduced expression of p-EGFR by a-screen assay using AlphaScreen SureFire Cellular Kinase Assay Kit (PerkinElmer LAS; data not shown).
Because HMQ1611-induced growth inhibition was observed in MDA-MB-231 cells after HMQ1611 treatment for 48 hours, we investigated the effect of HMQ1611 on EGFR signaling pathway in MDA-MB-231 cells. As shown by immunoblotting, the levels of phosphorylated EGFR, phosphorylated ERK1/2, and phosphorylated AKT proteins were decreased after HMQ1611 treatment for 48 hours (Fig. 3B) . The cells lysates were subjected to Western blot analysis using anti-EGFR, anti-p-EGFR, anti-MEK1/2, anti-p-MEK1/2, anti-ERK1/2, antip-ERK1/2, anti-AKT, anti-p-AKT, anti-PLCg, anti-p-PLCg, and anti-GAPDH antibodies. Data were represented as means AE SEM. Ã , P < 0.05; ÃÃ , P < 0.01 by ANOVA, compared with the control.
HMQ1611 inhibits tumor growth in mouse model
To determine the effects of HMQ1611 on breast cancer in vivo, we used the ZR-75-30 xenograft mouse tumor model. HMQ1611 treatment was initiated when tumors were palpable and continued 21 days. Table 1 showed that there was significant reduction of tumor weight in the mice treated with HMQ1611 compared with the vehicle control tumor-bearing mice. No body weight loss and any other abnormities were observed in the HMQ1611-treated mice indicating there were not toxic effects in our treatment regimen. Moreover, ERa expression levels were significantly reduced in tumor-bearing mice treated with HMQ1611 in a dose-dependent manner (Fig. 4) .
Discussion
The main findings of this study is that HMQ1611, a novel taspine derivative, can inhibit breast cancer cell growth in cultured cancer cells and tumor-bearing in vivo models by targeting ERa and EGFR. HMQ1611 reduced breast cancer cell proliferation and blocked cancer cells at the S stage. Moreover, HMQ1611 reduced ERa expression and downregulated membrane ERa mediate MAPK signaling in response to E2 and EGFR/ERK1/2, EGFR/PI3K/ AKT pathways. Our findings showed that HMQ1611 can be a potential novel agent for intervention with one compound targeting 2 major pathways involved in breast cancer development.
Breast cancer is a common cancer with high mortality among women. Anti-ER therapy is one of the common used treatments in the cancer clinics. However, long-term anti-ER treatment results in drug resistance that may be likely due to activation EGFR signaling pathways (19) (20) (21) . Thus, a strategy that dual blockade of EGFR and ER pathways is an important issue in antibreast cancer drug development. In this study, we found that our newly synthesized compound, mRNA and protein expression. More recently it has been reported that ERa associated with membrane mediated MAPK activation induced by estrogen. Downregulation of ERa with specific small inhibitory RNAs blocked E2-induced MAPK phosphorylation (15, 44, 45) . We wondered whether membrane-associated ERa also mediated the effect of HMQ1611 on MAPK signaling. In our experiments, we evaluated MAPK signaling in cells transfected with ERa siRNA or treated with HMQ1611. It was found that decreased ERa caused by specific siRNA led to downregulation of p-ERK1/2, suggesting that HMQ1611 might block MAPK signaling through modulating membrane-associated ERa and finally inhibited cell proliferation. Taken together, our data suggested that HMQ1611 reduced breast cancer cell growth via ERa-linked signaling pathway in ERa expression-positive cells.
Given HMQ1611 also reduced cancer cell growth in ERa expression-negative cells: MDA-MB-231 and SK-BR-3, we thought there must be an alternative target. Indeed, we found that HMQ1611 also reduced EGF-induced phosphorylated EGFR, phosphorylated ERK1/2, and phosphorylated AKT in both ZR-75-30 and MDA-MB-231 cells, suggesting that HMQ1611 downregulates the EGFR/MAPK and EGFR/PI3K/AKT pathways. MAPK and PI3K/AKT are 2 major signaling pathways controlling cell survival and cell proliferation pathways (27) (28) (29) . Thus, our data indicated that EGFR is an alternative target for HMQ1611 in ERa expression-negative cells.
The inhibitory effect of HMQ1611 on breast cancer can also be monitored in vivo. In vivo experiments showed no adverse effects of HMQ1611 when ingested by mice. In addition, we found that HMQ1611 significantly reduced tumor size and weight in tumor-bearing mice compared with vehicle-treated mice in a dosedependent manner suggesting that HMQ1611 can be a very good candidate for breast cancer intervention. The decreased tumor size was attributed to the reduced tumor cells through specific downregulating ERa expression, which was measured by immunohistochemical staining of tumor tissues.
In summary, we have characterized a novel taspine derivative, HMQ1611 has an anticancer effects in breast cancer cells and in vivo tumor-bearing mice. As depicted in Fig. 5 , the inhibitory effects of HMQ1611 on breast cancer cell are through 2 pathways: (i) ERa pathway: HMQ1611 regulated ERa expression and membraneassociated E2/ERa pathway, membrane-associated E2/ ERa pathway cross-talks with the MAPK pathway, in response to reduced membrane-associated ERa, MAPK activity is suppressed and (ii) EGFR pathway: HMQ1611 regulated EGF-induced activation of the EGFR as well as the downstream pathways such as MAPKs and PI3K/AKT. In brief, the inhibitory effects of HMQ1611 are through ERa pathway, and EGFR/MAPK and EGFR/PI3K/AKT pathways in breast cancer cells. This study suggests that HMQ1611 can be a potential drug candidate for combating breast cancer.
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